Skip to main content
Clinical Trials/NL-OMON56613
NL-OMON56613
Not yet recruiting
Not Applicable

anguage, speech and motor function in mild cognitive impairment due to AD and Alzheimer*s disease - Language, speech, motor function in MCI due to AD and AD

Hanzehogeschool Groningen0 sites208 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Hanzehogeschool Groningen
Enrollment
208
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Hanzehogeschool Groningen

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study:
  • A subject with MCI with a likelihood of underlying AD pathophysiology must meet
  • the following criteria:
  • \* Established diagnosis of MCI due to AD with a likelihood according to NIA\-AA
  • criteria (Albert et al., 2011\).
  • \* A score of stage three on the Global Deterioration Scale (GDS) (Reisberg et
  • al., 1982\).
  • A subject with AD must meet the following criteria:
  • \* Established diagnosis of AD (amnestic or non\-amnestic) or etiologically mixed
  • presentation of AD according to DSM\-5 (American Psychiatric Association, 2013\)

Exclusion Criteria

  • A subject with MCI due to AD or AD who meets the following criteria will be
  • excluded from participation in this study:
  • \* Having a neurological or neurodegenerative disease or disorder that may be
  • contributing to cognitive impairment above and beyond that caused by AD or
  • mixed AD; Down\*s syndrome, other subtypes of dementia, autism spectrum disorder.
  • \* Having an established diagnosis of a psychiatric disorder, e.g.
  • schizophrenia, depression.
  • All subjects in the control group who meets following criteria will be excluded
  • from participation in this study:
  • \* Suffers from a neurological, neurodegenerative or psychiatric disease or

Outcomes

Primary Outcomes

Not specified

Similar Trials